Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab
Open Access
- 28 March 2014
- journal article
- asthma and-lower-airway-disease
- Published by Elsevier BV in Journal of Allergy and Clinical Immunology
- Vol. 134 (3), 560-567.e4
- https://doi.org/10.1016/j.jaci.2014.02.007
Abstract
No abstract availableKeywords
Funding Information
- Genentech
This publication has 16 references indexed in Scilit:
- Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthmaAllergy, 2011
- Baseline characteristics of patients enrolled in EXCELS: a cohort studyAnnals of Allergy, Asthma & Immunology, 2009
- Cancer risk in hospitalised asthma patientsBritish Journal of Cancer, 2009
- Atopic diseases, immunoglobulin E and risk of cancer of the prostate, breast, lung and colorectumInternational Journal of Cancer, 2006
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004
- The effect of treatment with omalizumab, an anti‐IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthmaAllergy, 2004
- Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthmaClinical & Experimental Allergy, 2004
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- A prospective study of cancer incidence in a cohort examined for allergyAllergy, 1995
- Cancer Incidence among 78 000 Asthmatic PatientsInternational Journal of Epidemiology, 1993